Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.64 |
| ▸ | GSK3B | P49841 | 5/20 | 0.64 |
| ▸ | ITK | Q08881 | 7/20 | 0.63 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.61 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.61 |
| ▸ | WNT1 | P04628 | 4/20 | 0.57 |
| ▸ | CLK2 | P49760 | 4/20 | 0.56 |
| ▸ | CLK3 | P49761 | 4/20 | 0.56 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23534362 | 0.86 | DYRK1A (0.62) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL28809217 | 0.84 | IKBKE (0.63) | DYRK1AGSK3BITKIKBKETBK1 | |
| SCHEMBL29753969 | 0.84 | IKBKE (0.63) | DYRK1AGSK3BITKIKBKETBK1 | |
| SCHEMBL23534397 | 0.82 | GSK3B (0.70) | DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL23533876 | 0.80 | DYRK1A (0.71) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL14712554 | 0.80 | ITK (0.68) | DYRK1AGSK3BITKWNT1CLK2 | |
| SCHEMBL14699252 | 0.79 | ITK (0.86) | ITKSCDSCD5AURKA | |
| SCHEMBL5716427 | 0.78 | DYRK1A (0.82) | DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL14699430 | 0.78 | ITK (1.00) | ITKSCDSCD5AURKA | |
| SCHEMBL21292283 | 0.78 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867718-B | Indazole derivatives and use thereof | 韩国化学研究院 | 2024-10-01 | — | — | CN | claimed |
| CN-114867718-A | Novel indazole derivative and use thereof | 韩国化学研究院 | 2022-08-05 | — | — | CN | claimed |
| WO-2021125802-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | claimed |
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-07-31 | — | — | US | disclosed |
| CN-114867718-B | Indazole derivatives and use thereof | 韩国化学研究院 | 2024-10-01 | — | — | CN | disclosed |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) | 2023-04-13 | — | — | US | disclosed |
| EP-4079732-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-114867718-A | Novel indazole derivative and use thereof | 韩国化学研究院 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021125802-A1 | NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243181-A2 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | DYRK1A 573/4885GSK3B 956/4885ITK 1623/4885 |
| US-20230116733-A1 | NOVEL INDAZOLE DERIVATIVE AND USE THEREOF | TRIB2, YAP1, IDO2 | DYRK1A 573/4885GSK3B 956/4885ITK 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.